Jing Yuan Tan

ORCID: 0000-0001-5770-4701
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • COVID-19 Clinical Research Studies
  • Lymphoma Diagnosis and Treatment
  • COVID-19 and healthcare impacts
  • Venous Thromboembolism Diagnosis and Management
  • Hematopoietic Stem Cell Transplantation
  • Long-Term Effects of COVID-19
  • Viral-associated cancers and disorders
  • Infection Control and Ventilation
  • Chronic Lymphocytic Leukemia Research
  • CNS Lymphoma Diagnosis and Treatment
  • Respiratory viral infections research
  • Retinal and Macular Surgery
  • Hepatitis B Virus Studies
  • SARS-CoV-2 and COVID-19 Research
  • Mesenchymal stem cell research
  • Hepatitis C virus research
  • COVID-19 and Mental Health
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Chronic Myeloid Leukemia Treatments
  • Cancer Cells and Metastasis
  • COVID-19 epidemiological studies
  • Acute Lymphoblastic Leukemia research
  • Rheumatoid Arthritis Research and Therapies
  • Intraocular Surgery and Lenses
  • Dermatological and COVID-19 studies

Singapore General Hospital
2012-2025

First Affiliated Hospital of Zhengzhou University
2025

Henan Provincial Institute of Occupational Health
2025

National Cancer Centre Singapore
2024

Kunming Medical University
2024

Yan'an Hospital Affiliated To Kunming Medical University
2024

Zunyi Medical University
2023

SingHealth
2020-2022

Affiliated Hospital of North Sichuan Medical College
2010-2019

Dana-Farber Cancer Institute
2013

In the current COVID-19 pandemic, aggressive Infection Prevention and Control (IPC) measures have been adopted to prevent health care-associated transmission of COVID-19. We evaluated impact a multimodal IPC strategy originally designed for containment on rates other hospital-acquired-infections (HAIs).

10.1016/j.ajic.2020.10.019 article EN other-oa American Journal of Infection Control 2020-11-04

Hospitalisations for acute exacerbations of COPD (AECOPD) carry significant morbidity and mortality. Respiratory viral infections (RVIs) are the most common cause AECOPD associated with worse clinical outcomes. During COVID-19 pandemic, public health measures, such as social distancing universal masking, were originally implemented to reduce transmission SARS-CoV-2; these measures subsequently also observed other circulating RVIs. In this study, we report a sustained decrease in hospital...

10.1136/thoraxjnl-2020-216083 article EN other-oa Thorax 2020-12-03

Abstract COVID-19 caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and other respiratory viral (non-CoV-2-RV) infections are associated with thrombotic complications. The differences in prothrombotic potential between SARS-CoV-2 non-CoV-2-RV have not been well characterised. We compared the rates these two groups of patients directly further delved into their coagulation profiles. In this single-center, retrospective cohort study, all consecutive admitted January 15th...

10.1038/s41598-021-81166-y article EN cc-by Scientific Reports 2021-01-19

Abstract Introduction A high incidence of mortality and severe COVID‐19 infection was reported in hematopoietic stem cell transplant (HSCT) recipients during the early phases pandemic; however, outcomes with subsequent acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants, such as omicron variant, have yet to be reported. Additionally, rollout vaccinations pandemic waves may modify disease severity this immunocompromised population. We describe among a highly vaccinated population...

10.1111/tid.14024 article EN Transplant Infectious Disease 2023-01-30

Abstract Pathological cardiac hypertrophy, often triggered by the excessive production and accumulation of reactive oxygen nitrogen species (RONS), may ultimately lead to heart failure. The treatment myocardial hypertrophy involves antioxidant stress therapy. In this study, coordinating curcumin with ferric ions during synthesis Prussian blue nanoparticles, a blue‐curcumin (PB‐Cur) nanozyme is successfully engineered exceptional (RONS) elimination capabilities. Following PVP modification,...

10.1002/adhm.202404201 article EN Advanced Healthcare Materials 2025-04-24

Prolonged shedding/relapse of COVID-19 infection has been reported, particularly in patients who received anti-CD20 agents (eg. rituximab). However, cases occult COVID-19, which SARS-CoV-2 persistence lung parenchyma is diagnosed despite clearance from nasopharyngeal (NP) specimens, are uncommon. We describe two immunocompromised patients. Both had rituximab previously. initially presented as ground-glass infiltrates on imaging; the diagnosis was originally not suspected due to repeated...

10.1016/j.idcr.2022.e01611 article EN cc-by-nc-nd IDCases 2022-01-01

An important role for plexinD1 in thymic development is inferred from studies of germline Plxnd1 knockout (KO) mice where mislocalized CD69(+) thymocytes as well ectopic subcapsular medullary structures were observed. Given embryonic lethality the (-/-) genotype, fetal liver transplantation was employed these prior analyses. Such hematopoietic reconstitution may have transferred KO endothelial and/or epithelial stem cells addition to lymphoid progenitors, thereby contributing that phenotype....

10.3389/fimmu.2013.00392 article EN cc-by Frontiers in Immunology 2013-01-01

Abstract During this coronavirus disease 2019 (COVID‐19) pandemic, physicians have the important task of risk stratifying patients who present with acute respiratory illnesses. Clinical presentation COVID‐19, however, can be difficult to distinguish from other viral infections. Thus, identifying clinical features that are strongly associated COVID‐19 in comparison viruses aid stratification and testing prioritization especially situations where resources for virological isolation facilities...

10.1002/jmv.26486 article EN Journal of Medical Virology 2020-09-03

Abstract Background Arterial and venous thrombosis are reported to be common in critically ill COVID-19 patients. Method results This is a national multicenter retrospective observational study involving all consecutive adult patients who required intensive care units (ICU) admission between 23 January 2020 30 April Singapore. One hundred eleven were included the arterial thrombotic rates ICU 1.8% ( n = 2) 9.9% 11), respectively. Major bleeding rate was 14.8% 16). Conclusions Critically...

10.1186/s12959-021-00268-9 article EN cc-by Thrombosis Journal 2021-03-08

We analyzed the prognostic factors for treatment outcomes amongst 34 patients with adult Burkitt lymphoma (BL) who received rituximab standard first-line chemotherapy. Seven had human immunodeficiency virus (HIV)-associated BL. Overall, we observed a complete remission (CR) rate of 91.2%, and 10-year progression-free survival (PFS) overall (OS) was 84.8 88.2%, respectively. In concomitant HIV, prognosis not different PFS 100% OS 88.2%. The majority (71.4%) HIV-associated BL dose-adjusted...

10.1080/10428194.2022.2027402 article EN Leukemia & lymphoma/Leukemia and lymphoma 2022-02-19

Proliferative vitreoretinopathy (PVR) is the leading cause of failure surgery for rhegmatogenous retinal detachment. Although indirect evidence suggests that this disease might be autoimmune in nature, direct proof hypothesis lacking. The purpose study was to determine a murine model whether PVR can develop absence T- or B-cell immunity. Four- six-week-old Rag-1 gene knockout (KO) and congenic wild-type mice (WT) on C57.Bl/6 background were studied. induced by intravitreal injection 3 μl...

10.1038/eye.2012.52 article EN cc-by-nc-nd Eye 2012-03-30

Muscle involvement, termed polymyositis, is an uncommon manifestation of graft-versus-host disease (GvHD) in which the upper and lower limbs are commonly affected. However, respiratory failure due to diaphragmatic weakness has rarely been reported. Diagnosis usually based on a combination elevated muscle enzyme levels blood, neurophysiological studies, biopsies.

10.31547/bct-2023-040 article EN BLOOD CELL THERAPY / The official journal of APBMT 2024-01-01

Rituximab-induced interstitial lung disease (R-ILD) has aroused more concern in recent years. Anti-TNF-α treatment been suggested for the of severe R-ILD, due to plausible suggestion that its pathogenesis is related TNF-α. This commentary aimed comment on role TNF-α antagonists R-ILD.Although most R-ILD patients respond well glucocorticoids, other options are needed who refractory conventional treatment. Contrary expectations, antagonist etanercept brought no benefit R-ILD. Moreover,...

10.1111/jcpt.12252 article EN Journal of Clinical Pharmacy and Therapeutics 2015-03-24
Coming Soon ...